Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- FY2023 COVID Booster Program Begins for Elderly, Health Workers
May 9, 2023
- Japan Shoots for 80% Replacement Rate in 60% of All Biosimilar APIs by FY2029
May 8, 2023
- PMDA, NHO Ink Database Deal, Data on 9 Million-Plus People to Be Available
May 8, 2023
- MHLW to Decide on Policy for Real-Time Supply Info System within FY2023: Official
May 8, 2023
- Japan Ends Priority Review for COVID Products with Severity Downgrade
May 8, 2023
- Ferring Japan Faces Biz Improvement Order for GMP Violation at Overseas Site
May 1, 2023
- Japan Approves Mefeego as First Abortion Pill
May 1, 2023
- LDP League Calls for Generic Market Entry Rules to Ensure Supply: Draft Proposal
April 28, 2023
- Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
April 28, 2023
- Lawmakers’ League on Pollen Allergy Boosts Up
April 27, 2023
- As Japan Mulls Pushing Back Fee Revisions, Chuikyo Reps Fret Impact on Drug Price Updates
April 27, 2023
- Shionogi CEO Presses Govt for G7 Debate on Pull Incentives for Antibiotics
April 27, 2023
- Mpox Cases Hit 120 in Japan: MHLW
April 27, 2023
- Chuikyo OKs CEA Discussion Timeline for FY2024 Reform; Industry Hearing Set for August, November
April 27, 2023
- Ultomiris Clears Japan Panel Review for NMOSD Approval
April 27, 2023
- Japan Panel to Draw Up Revision Outline for Basic Blood Products Policy by September, Eyes Profitability Improvement
April 26, 2023
- Skyrizi in Line for Palmoplantar Pustulosis Nod, Vanflyta for 1st Line AML
April 25, 2023
- Shelf Life for Lagevrio Extended to 36 Months in Japan
April 24, 2023
- MHLW Panel OKs 192 More Health Damage Claims for COVID-19 Vaccines
April 24, 2023
- Japan’s Diet Enacts Bill to Establish Pandemic Response Agency
April 24, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…